I am a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis hematopoiesis: (hi-mat-uh-poy-EE-suss) The process of making blood cells in the bone marrow. and myeloid cancers, including acute myeloid leukemia acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone marrow and become to numerous. This slows production of red blood cells and platelets. Some cases of MDS become… (AML) and myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at… (MDS). My clinical and research interests focus on RNA regulation in hematologic malignancies. Specifically, I investigate how mutations in splicing factors affect RNA processing and contribute to disease progression. These genetic mutations can occur at any stage of life, leading to complex disorders that are often challenging to diagnose and treat.
In the laboratory, we utilize advanced genomic technologies, such as RNA sequencing and ribosome profiling, to explore how disrupted RNA processing drives malignancy. The primary goal of this research is to uncover novel therapeutic targets and develop innovative immunotherapy approaches aimed at improving patient outcomes in high-risk myeloid malignancies. By examining these questions through the lens of RNA regulation, our work aims to bridge clinical care and fundamental research to better understand and treat disorders of clonal hematopoiesis and myeloid cancers.